StockNews.com Begins Coverage on Cellectis (NASDAQ:CLLS)

Analysts at StockNews.com started coverage on shares of Cellectis (NASDAQ:CLLS) in a note issued to investors on Sunday. The firm set a “sell” rating on the biotechnology company’s stock.

Cellectis Stock Down 3.2 %

Shares of Cellectis stock opened at $1.84 on Friday. Cellectis has a 52-week low of $0.96 and a 52-week high of $3.77. The company has a 50 day moving average of $2.17 and a 200 day moving average of $2.34. The company has a quick ratio of 1.92, a current ratio of 1.92 and a debt-to-equity ratio of 0.39. The company has a market capitalization of $102.27 million, a P/E ratio of -1.43 and a beta of 3.09.

Cellectis (NASDAQ:CLLS) last issued its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.05. The business had revenue of $9.50 million during the quarter, compared to the consensus estimate of $6.00 million. Cellectis had a negative net margin of 401.83% and a negative return on equity of 78.90%. As a group, research analysts forecast that Cellectis will post -0.54 EPS for the current fiscal year.

Hedge Funds Weigh In On Cellectis

A number of institutional investors have recently modified their holdings of CLLS. XTX Topco Ltd acquired a new position in shares of Cellectis in the 2nd quarter valued at $29,000. First Affirmative Financial Network acquired a new position in Cellectis in the 3rd quarter valued at $45,000. Principal Financial Group Inc. increased its stake in Cellectis by 2.9% in the 2nd quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock valued at $817,000 after buying an additional 12,467 shares during the period. Baillie Gifford & Co. increased its stake in Cellectis by 1.3% in the 1st quarter. Baillie Gifford & Co. now owns 827,248 shares of the biotechnology company’s stock valued at $2,192,000 after buying an additional 10,605 shares during the period. Finally, Long Focus Capital Management LLC increased its stake in Cellectis by 2.9% in the 2nd quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock valued at $8,634,000 after buying an additional 130,000 shares during the period. 63.90% of the stock is owned by institutional investors and hedge funds.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.